Cargando…

Risk Factors for Severe Erectile Dysfunction after Focal Therapy with High-Intensity Focused Ultrasound for Prostate Cancer

The present study aimed to analyze the effect of predisposing clinical factors for severe erectile dysfunction (ED) in patients treated with focal therapy using high-intensity focused ultrasound (HIFU) for localized prostate cancer (PC). Patients without severe ED (International Index of Erectile Fu...

Descripción completa

Detalles Bibliográficos
Autores principales: Shoji, Sunao, Kuroda, Satoshi, Uemura, Kohei, Oda, Kazuya, Kano, Tatsuo, Ogawa, Takahiro, Umemoto, Tatsuya, Nakano, Mayura, Kawakami, Masayoshi, Nitta, Masahiro, Hasegawa, Masanori, Miyajima, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687416/
https://www.ncbi.nlm.nih.gov/pubmed/36359396
http://dx.doi.org/10.3390/biomedicines10112876
_version_ 1784835999323389952
author Shoji, Sunao
Kuroda, Satoshi
Uemura, Kohei
Oda, Kazuya
Kano, Tatsuo
Ogawa, Takahiro
Umemoto, Tatsuya
Nakano, Mayura
Kawakami, Masayoshi
Nitta, Masahiro
Hasegawa, Masanori
Miyajima, Akira
author_facet Shoji, Sunao
Kuroda, Satoshi
Uemura, Kohei
Oda, Kazuya
Kano, Tatsuo
Ogawa, Takahiro
Umemoto, Tatsuya
Nakano, Mayura
Kawakami, Masayoshi
Nitta, Masahiro
Hasegawa, Masanori
Miyajima, Akira
author_sort Shoji, Sunao
collection PubMed
description The present study aimed to analyze the effect of predisposing clinical factors for severe erectile dysfunction (ED) in patients treated with focal therapy using high-intensity focused ultrasound (HIFU) for localized prostate cancer (PC). Patients without severe ED (International Index of Erectile Function-5 [IIEF-5] score ≥ 8) before focal HIFU therapy were included. A total of 92 of the 240 patients met the inclusion criteria and were included. The rate of severe ED (IIEF-5 ≤ 7) was 36% 12 months after treatment. Multivariable logistic regression analysis showed that the pre-procedural lower IIEF-5 score (odds ratio [OR] 0.812, p = 0.005), the pre-procedural lower score of the sexual domain of the Expanded Prostate Cancer Index Composite (OR 0.960, p = 0.038), and the treatment of the edge of the peripheral zone (PZ) in proximity to the neurovascular bundle (NVB) [treated vs. untreated, OR 8.048, p = 0.028] were significant risk factors for severe ED at 12 months after treatment. In conclusion, pre-procedural lower erectile function and treatment of the part in proximity to the NVB were significant risk factors for severe ED after focal therapy.
format Online
Article
Text
id pubmed-9687416
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96874162022-11-25 Risk Factors for Severe Erectile Dysfunction after Focal Therapy with High-Intensity Focused Ultrasound for Prostate Cancer Shoji, Sunao Kuroda, Satoshi Uemura, Kohei Oda, Kazuya Kano, Tatsuo Ogawa, Takahiro Umemoto, Tatsuya Nakano, Mayura Kawakami, Masayoshi Nitta, Masahiro Hasegawa, Masanori Miyajima, Akira Biomedicines Article The present study aimed to analyze the effect of predisposing clinical factors for severe erectile dysfunction (ED) in patients treated with focal therapy using high-intensity focused ultrasound (HIFU) for localized prostate cancer (PC). Patients without severe ED (International Index of Erectile Function-5 [IIEF-5] score ≥ 8) before focal HIFU therapy were included. A total of 92 of the 240 patients met the inclusion criteria and were included. The rate of severe ED (IIEF-5 ≤ 7) was 36% 12 months after treatment. Multivariable logistic regression analysis showed that the pre-procedural lower IIEF-5 score (odds ratio [OR] 0.812, p = 0.005), the pre-procedural lower score of the sexual domain of the Expanded Prostate Cancer Index Composite (OR 0.960, p = 0.038), and the treatment of the edge of the peripheral zone (PZ) in proximity to the neurovascular bundle (NVB) [treated vs. untreated, OR 8.048, p = 0.028] were significant risk factors for severe ED at 12 months after treatment. In conclusion, pre-procedural lower erectile function and treatment of the part in proximity to the NVB were significant risk factors for severe ED after focal therapy. MDPI 2022-11-10 /pmc/articles/PMC9687416/ /pubmed/36359396 http://dx.doi.org/10.3390/biomedicines10112876 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Shoji, Sunao
Kuroda, Satoshi
Uemura, Kohei
Oda, Kazuya
Kano, Tatsuo
Ogawa, Takahiro
Umemoto, Tatsuya
Nakano, Mayura
Kawakami, Masayoshi
Nitta, Masahiro
Hasegawa, Masanori
Miyajima, Akira
Risk Factors for Severe Erectile Dysfunction after Focal Therapy with High-Intensity Focused Ultrasound for Prostate Cancer
title Risk Factors for Severe Erectile Dysfunction after Focal Therapy with High-Intensity Focused Ultrasound for Prostate Cancer
title_full Risk Factors for Severe Erectile Dysfunction after Focal Therapy with High-Intensity Focused Ultrasound for Prostate Cancer
title_fullStr Risk Factors for Severe Erectile Dysfunction after Focal Therapy with High-Intensity Focused Ultrasound for Prostate Cancer
title_full_unstemmed Risk Factors for Severe Erectile Dysfunction after Focal Therapy with High-Intensity Focused Ultrasound for Prostate Cancer
title_short Risk Factors for Severe Erectile Dysfunction after Focal Therapy with High-Intensity Focused Ultrasound for Prostate Cancer
title_sort risk factors for severe erectile dysfunction after focal therapy with high-intensity focused ultrasound for prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687416/
https://www.ncbi.nlm.nih.gov/pubmed/36359396
http://dx.doi.org/10.3390/biomedicines10112876
work_keys_str_mv AT shojisunao riskfactorsforsevereerectiledysfunctionafterfocaltherapywithhighintensityfocusedultrasoundforprostatecancer
AT kurodasatoshi riskfactorsforsevereerectiledysfunctionafterfocaltherapywithhighintensityfocusedultrasoundforprostatecancer
AT uemurakohei riskfactorsforsevereerectiledysfunctionafterfocaltherapywithhighintensityfocusedultrasoundforprostatecancer
AT odakazuya riskfactorsforsevereerectiledysfunctionafterfocaltherapywithhighintensityfocusedultrasoundforprostatecancer
AT kanotatsuo riskfactorsforsevereerectiledysfunctionafterfocaltherapywithhighintensityfocusedultrasoundforprostatecancer
AT ogawatakahiro riskfactorsforsevereerectiledysfunctionafterfocaltherapywithhighintensityfocusedultrasoundforprostatecancer
AT umemototatsuya riskfactorsforsevereerectiledysfunctionafterfocaltherapywithhighintensityfocusedultrasoundforprostatecancer
AT nakanomayura riskfactorsforsevereerectiledysfunctionafterfocaltherapywithhighintensityfocusedultrasoundforprostatecancer
AT kawakamimasayoshi riskfactorsforsevereerectiledysfunctionafterfocaltherapywithhighintensityfocusedultrasoundforprostatecancer
AT nittamasahiro riskfactorsforsevereerectiledysfunctionafterfocaltherapywithhighintensityfocusedultrasoundforprostatecancer
AT hasegawamasanori riskfactorsforsevereerectiledysfunctionafterfocaltherapywithhighintensityfocusedultrasoundforprostatecancer
AT miyajimaakira riskfactorsforsevereerectiledysfunctionafterfocaltherapywithhighintensityfocusedultrasoundforprostatecancer